Labcorp Holdings (LH) has experienced a notable fluctuation in recent transactions, with insider and institutional sales alongside concurrent buys being apparent. The company's CEO, Adam Schechter, and EVP Brian Caveney selling a combined approximate 10,000 shares. However, Victory Capital Management made a significant purchase of over 440,000 shares.
LH's role in
U.S. diagnostics has been a recurring theme. Labcorp announced an ambitious revenue growth plan for FY26 and projected strong Q2 earnings growth.
Q3 Earnings, however, fell short of expectations even though revenues exceeded predictions. LH also announced a dividend of $0.72 per share. Despite this, the share
price declined 10.5% over the past three months. A
major shift in the company's dynamics could be seen in the recent
contract research slowdown and the push toward oncology. These strategic moves could become potential game changers for Labcorp. Recently, Labcorp raised its annual profit forecast citing strong diagnostic testing demand and disclosed its full year guidance after Q2 earnings surpassed Wall Street expectations. Further, Labcorp completed the
Fortrea spin-off and has announced
strategic alliances for diagnostic laboratory services.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 07 Nov 2016 08:00:00 GMT to Fri, 06 Mar 2026 09:45:40 GMT -
Rating 4
- Innovation -3
- Information 7
- Rumor -6
